AVE 20.0% 0.3¢ avecho biotechnology limited

the positive side if elixia launch ?fails?, page-8

  1. 5,260 Posts.
    lightbulb Created with Sketch. 242
    $10-12 mil from tiny sales per outlet. This is my base/worst case scenario.


    TL, this is indeed a worst/base case scenario. In fact if anyone want's to take me up I'd make a symbolic wager of few pints of lager that revenue of that order will be achieved no later than year's end and that is only the pointy end of the spear.

    I'd estimate that by the end of 2012, revenues from the cellulite cream alone will exceed $100 million annually and sales will still be growing.

    This is the cash cow that will fund everything else that this company wants to do.

    Ditto Calzada; they are also looking at the same cellucreme-funded scenario. And their share price has been reflecting this - tripling since last October. POH will do the same once the dummies stop selling cheap.

 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
(20min delay)
Last
0.3¢
Change
0.001(20.0%)
Mkt cap ! $9.507M
Open High Low Value Volume
0.3¢ 0.3¢ 0.3¢ $408 154.2K

Buyers (Bids)

No. Vol. Price($)
61 90794613 0.2¢
 

Sellers (Offers)

Price($) Vol. No.
0.3¢ 54998583 13
View Market Depth
Last trade - 16.10pm 19/07/2024 (20 minute delay) ?
AVE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.